Ultime notizie per PMGC Holdings (NASDAQ:ELAB) Azioni

Elevai Labs

PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.

PMGC Holdings Inc

<a href="https://x.com/realDonaldTrump/status/1909258878035828788" title="https://x.com/realDonaldTrump/status/1909258878035828788">https://x.com/realDonaldTrump/status/1909258878035828788</a>

Macro Economic Events

News

Politics

Economics

General

President Trump Posts On X "The United States has a chance to do something that should have been done DECADES AGO. Don't be Weak! Don't be Stupid! Don't be a PANICAN (A new party based on Weak and Stupid people!). Be Strong, Courageous, and Patient, and GREATNESS will be the result!"

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Compass Point analyst Giuliano Bologna upgraded Ally Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>) from Neutral to Buy and raised the price target from $37 to $41. Ally Financial shares closed at $32.12 on Friday. <a href="https://www.benzinga.com/quote/ALY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Jonathan Matuszewski upgraded the rating for The Scotts Miracle-Gro Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) from Hold to Buy and lowered the price target from $72 to $69. Scotts Miracle Gro shares closed at $51.41 on Friday. <a href="https://www.benzinga.com/quote/SMG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Paul Lejuez upgraded Dollar General Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) from Sell to Neutral and raisesd the price target from $69 to $101. Dollar General shares closed at $92.62 on Friday. <a href="https://www.benzinga.com/quote/DG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird analyst David George upgraded the rating for Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>) from Neutral to Outperform and maintained the price target of $47. Fifth Third Bancorp shares closed at $33.75 on Friday. <a href="https://www.benzinga.com/quote/FITB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic analyst Hamilton Faber upgraded Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) from Neutral to Buy and announced a $100 price target. Roku shares closed at $55.28 on Friday.  <a href="https://www.benzinga.com/quote/ROKU/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ROKU stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image is-resized"><img decoding="async" src="blob:https://editorial.benzinga.com/b1d2fb5c-b882-4b56-8b24-a4753f96c5ca" alt="" style="width:516px;height:auto" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44665280/how-to-earn-500-a-month-from-walgreens-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Walgreens Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Image via Shutterstock

Upgrades

Markets

Analyst Ratings

ALLY

FITB

ROKU

This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

<a href="https://www.federalreserve.gov/newsevents/speech/kugler20250407a.htm" title="https://www.federalreserve.gov/newsevents/speech/kugler20250407a.htm">https://www.federalreserve.gov/newsevents/speech/kugler20250407a.htm</a>

Federal Reserve

Fed's Kugler Says We Haven't Seen Q1 Data On Economic Activity; Sems To Be Front-loading Of Auto Sales; Q1 May Show More Strength Than We May Imagine; Consumer Confidence Moderating; Some Step Back In Retail Sales; A Lot Of Uncertainty; Uncertainty Holding Back Business Investment; Need To Pay Attention To That; Fed Has To Be Careful In How To Navigate; Right Now Inflation Is More Pressing

Fed's Kugler Says Moderately Restrictive Interest Rates Affect Households, But Inflation Also Affects Households In Negative Way; So Far Economic Activity Data Looks Positive, For Q4

Benzinga Note: Market continues to be volatile after the White House Calls Hassett Tariff Headline 'Fake News' Amid Numerous Tariff Developments from EU, China.
Hassett was misquoted by numerous X accounts and sources as indicating that Trump was considering a 90-day pause in tariffs.

Fed's Kugler Says Tariffs, Shortages Are Important To Consider When Forecasting What Inflation Will Do; New Tariffs Will Be 'Consequential'; Have Already Started Seeing Some Increase In Prices; Inflation Expectations Have Moved Up, Mainly Short-term Expectations; For Now, It's Short-run Inflation Expectations Have Moved Up; For Now Long-run Inflation Expdctations Well-anchored; Committed To 2% Inflation Target; This Is A Priority, To Make Sure Inflation Does Not Move Up

<figure class="wp-block-image size-full"><img decoding="async" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/04/07151508/Screen_Shot_2025-04-06_at_10.56.45_PM-1.avif" alt="" class="wp-image-9950" /></figure>
<a href="https://earningshub.com/earnings-calendar/this-week?utm_source=marketmadness-newsletter.beehiiv.com&amp;utm_medium=referral&amp;utm_campaign=the-black-monday-breakdown" target="_blank" rel="noreferrer noopener"></a><a href="https://earningshub.com/earnings-calendar/this-week?utm_source=marketmadness-newsletter.beehiiv.com&amp;utm_medium=referral&amp;utm_campaign=the-black-monday-breakdown" target="_blank" rel="noreferrer noopener">This Week's Earnings Calendar</a>
Markets just wrapped up one of the toughest two-day stretches in recent memory, with a drop of over 10 percent. On Wednesday at 4 PM, President Trump announced a sweeping plan to impose "reciprocal" tariffs on every country around the globe.
Initially, investors responded with cautious optimism. A report from the Wall Street Journal suggested the tariffs would be limited to just 10 percent. That changed quickly. Trump presented a chart showing actual rates, and while 10 percent was the floor, many countries faced far steeper penalties, China was hit the hardest with a combined rate of 54 percent.
Markets began to slip after hours. By Thursday, the selloff accelerated. Major indexes each lost more than 4 percent, and yet some investors began calling it a buying opportunity. With the market already down over 10 percent year to date, it seemed like a fair bet.
But Friday morning brought a fresh headline: China would strike back with its own tariffs on US goods, totaling 34 percent. Markets opened lower and closed with a nearly 6 percent loss, another blow to an already volatile week.
Over the weekend, I poured through research, commentary, and analysis. One theme kept popping up: "Black Monday." That phrase brings back memories of 1987, and the fear that we might see a repeat began to spread among investors and analysts.
Global markets followed the same path. Asian exchanges opened sharply lower. Japan fell 6 percent out of the gate, and China dropped 9 percent. As I write this on Sunday evening, US futures are down more than 3 percent and have not seen a single moment of green.
Corrections like this are never easy, but they are normal. Long term investors should see times like these as moments to reassess, reframe, and possibly reenter. To borrow from&nbsp;The Art of War, "In the midst of chaos, there is also opportunity."
This will pass. It always does.
Keep your head up. Stay focused on the long term. And remember, investing rewards patience.
&#x2A;&#x2A;
Welcome to the WOLF Financial Newsletter.
Join over 13,000 savvy investors building wealth and mastering advanced investing strategies live on Twitter Spaces. Subscribe below to be part of the action:
<a target="_blank" rel="noreferrer noopener" href="https://marketmadness-newsletter.beehiiv.com/subscribe">Subscribe</a>
WOLF Financial has driven liquidity, user growth, and brand awareness across TradFi and Crypto through marketing, advisory, and partnership services. See more&nbsp;<a href="https://wolf.financial/?utm_source=marketmadness-newsletter.beehiiv.com&amp;utm_medium=newsletter&amp;utm_campaign=new-post" target="_blank" rel="noreferrer noopener">Here</a>.

Long Ideas

Market Summary

Broad U.S. Equity ETFs

Global

Opinion

The Black Monday Breakdown: This Week's Market Forecast

WIIM

Oil is trading lower, with crude dropping to 2021 levels, following OPEC+'s decision to accelerate production hikes. The market is also grappling with fears of a recession, fueled by President Trump's recent tariff announcements and China's retaliatory measures, which have heightened concerns over global demand.

<a href="https://x.com/realDonaldTrump/status/1909258777380974625" title="https://x.com/realDonaldTrump/status/1909258777380974625">https://x.com/realDonaldTrump/status/1909258777380974625</a>

Donald J. Trump Posts On X "Oil prices are down, interest rates are down (the slow moving Fed should cut rates!), food prices are down, there is NO INFLATION, and the long time abused USA is bringing in Billions of Dollars a week from the abusing countries on Tariffs that are already in place."

As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Alumis Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>)</h3>
<ul>
<li>On March 25, Alumis, Inc announced it entered into a collaboration and licensing agreement with Kaken Pharmaceuticals. Under the agreement, Alumis is licensing ESK-001, a drug aimed at treating immune dysregulation in various diseases, to Kaken for development, manufacturing and commercialization in Japan, limited to dermatologic applications.. The company's stock gained around 106% over the past month and has a 52-week high of $13.50.</li>
<li>RSI Value: 77.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ALMS Price Action: Shares of Alumis gained 17.7% to close at $10.05 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Chimerix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>)</h3>
<ul>
<li>On March 21, Chimerix reported quarterly losses of 25 cents per share which beat the analyst consensus estimate of a loss of 26 cents per share. The company reported quarterly sales of $57.00 thousand which missed the analyst consensus estimate of $75.00 thousand by 24.00 percent. The company's stock gained around 837% over the past six months and <a href="https://www.benzinga.com/quote/CMRX">has a 52-week high</a> of $8.54.</li>
<li>RSI Value: 82.7</li>
<li>CMRX Price Action: Shares of Chimerix closed at $8.53 on Friday.</li>
</ul>
<h3 class="wp-block-heading">Journey Medical Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DERM#NASDAQ">DERM</a>)</h3>
<ul>
<li>On April 1, Journey Medical Corporation named Ramsey Alloush as Chief Operating Officer. Claude Maraoui, President and Chief Executive Officer of Journey Medical, said, &#8220;Ramsey&#8217;s promotion to COO reflects his exceptional leadership and the critical role he has played in our Company&#8217;s growth. His deep understanding of our business and the industry uniquely positions him to drive our strategic initiatives forward, focusing on operational excellence and maximizing shareholder value.&#8221; The company's stock gained around 40% over the past month and has a 5<a href="https://www.benzinga.com/quote/DERM">2-week high</a> of $7.29.</li>
<li>RSI Value: 77.3</li>
<li>DERM Price Action: Shares of Journey Medical gained 9.1% to close at $7.19 on Friday.</li>
</ul>
Learn more about BZ Edge Rankings—click to see scores for other <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">stocks in the sector and see how they compare.</a> 
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44645517/wall-streets-most-accurate-analysts-give-their-take-on-3-health-care-stocks-with-over-4-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Health Care Stocks With Over 4% Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Short Ideas

Pre-Market Outlook

Trading Ideas

ALMS

CMRX

DERM

Top 3 Health Care Stocks That May Crash In Q2

U.S. stocks settled lower on Friday, with the Dow Jones index tumbling over 2,200 points during the session.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Mark Hughes
<ul>
<li>Analyst Firm: Truist Securities</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained a Buy rating on W. R. Berkley Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRB#NYSE">WRB</a>) and increased the price target from $68 to $80 on April 3. This analyst sees around 25% upside in the stock.</li>
<li>Recent News: On April 1, W. R. Berkley named Michael G. MacMullin President of Berkley Luxury Group.</li>
</ul>
Analyst: Matthew Carletti
<ul>
<li>Analyst Firm: Citizens Capital Markets</li>
<li>Ratings Accuracy: 84%</li>
<li>Latest Rating: Downgraded rating on ProAssurance Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRA#NYSE">PRA</a>) from Market Outperform to Market Perform on April 3.</li>
<li>Recent News: On March 19, ProAssurance announced it will be acquired by The Doctors Company for $25.00 per share in cash.</li>
</ul>
Analyst: Zachary Fadem 
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 84%</li>
<li>Latest Rating: Maintained an Overweight rating on RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) and slashed the price target from $375 to $300 on April 3. This analyst sees around 76% upside in the stock.</li>
<li>Recent News: On April 2, RH reported fourth-quarter financial results and missed its adjusted EPS and revenue estimates.</li>
</ul>
Analyst: Paul Newsome
<ul>
<li>Analyst Firm: Piper Sandler</li>
<li>Ratings Accuracy: 84%</li>
<li>Latest Rating: Maintained an Overweight rating on The Hanover Insurance Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) and increased the price target from $190 to $205 on April 1. This analyst sees around 35% upside in the stock.</li>
<li>Recent News: On April 3, The Hanover appointed Richard W. Lavey as Chief Operating Officer.</li>
</ul>
Analyst: Josh Sullivan
<ul>
<li>Analyst Firm: Benchmark</li>
<li>Ratings Accuracy: 83%</li>
<li>Latest Rating: Maintained a Buy rating on TAT Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TATT#NASDAQ">TATT</a>) and increased the price target from $30 to $35 on April 3. This analyst sees around 37% upside in the stock.</li>
<li>Recent News: On March 26, TAT Technologies reported a year-over-year increase in fourth-quarter financial results.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44665280/how-to-earn-500-a-month-from-walgreens-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Walgreens Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

Price Target

TATT

5 Stock Picks Last Week From Wall Street's Most Accurate Analysts

Barclays analyst Eddie Kim maintains Valaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAL#NYSE">VAL</a>) with a Equal-Weight and lowers the price target from $46 to $35.

Barclays Maintains Equal-Weight on Valaris, Lowers Price Target to $35

<a href="https://www.axios.com/2025/04/07/trump-pep-rally-house-republicans-donors" title="https://www.axios.com/2025/04/07/trump-pep-rally-house-republicans-donors">https://www.axios.com/2025/04/07/trump-pep-rally-house-republicans-donors</a>

'Trump To Hold "Pep Rally" For House Republicans And Big Donors Tuesday' - Axios

Barclays analyst David Anderson maintains Transocean (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) with a Overweight and lowers the price target from $4 to $3.5.

Barclays Maintains Overweight on Transocean, Lowers Price Target to $3.5

<a href="https://truthsocial.com/@realDonaldTrump/posts/114297331052690348" title="https://truthsocial.com/@realDonaldTrump/posts/114297331052690348">https://truthsocial.com/@realDonaldTrump/posts/114297331052690348</a>

President Trump Says Negotiations With Other Countries Will Begin Taking Place Immediately; Additional 50% China Tariffs Effective April 9 If China Does Not Withdraw 34% Tariff By April 8

Barclays analyst Eddie Kim maintains Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>) with a Overweight and lowers the price target from $39 to $29.

Barclays Maintains Overweight on Noble Corp, Lowers Price Target to $29

On Sunday, Woodside Energy Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDS#NYSE">WDS</a>) inked a binding deal to sell a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44659653/woodside-announces-louisiana-lng-partnership-with-stonepeak" rel="noreferrer noopener">40% stake in Louisiana LNG Infrastructure</a> LLC to Stonepeak.
As per the deal, Stonepeak plans to invest $5.7 billion in the development of the three-train, 16.5 mtpa foundation phase of Louisiana LNG.
The investment is expected to cover 75% of capital expenditure in 2025 and 2026, with development starting on January 1, 2025.
This significantly eases Woodside's capex burden, improves project economics, and strengthens cash flow ahead of revenue from its Scarborough Energy Project in Australia—enhancing capacity for shareholder returns.
The remaining 60% stake will be retained by Louisiana LNG LLC (HoldCo), operated by Woodside.
Meanwhile, InfraCo, managed by Woodside, holds the EPC agreement with Bechtel and, pending a final investment decision, will own and build the liquefaction infrastructure and shared facilities.
Under this arrangement, HoldCo will manage gas supply and LNG offtake.
Due to the accelerated nature of their capital contributions,
Stonepeak's total investment of $5.7 billion will be less than their nominal 40% ownership stake in InfraCo after adjusting for the time value of money.
HoldCo will cover the additional capital required if there are any cost overruns. This arrangement offers Stonepeak cost certainty while allowing HoldCo to capture potential capital expenditure savings.
The projected forward cost for the foundation phase of the Louisiana LNG project, starting from December 2024, is estimated at $900–$960 per tonne.
The transaction is expected to close in the second quarter of 2025, pending customary conditions precedent. Post-completion, Stonepeak is expected to make a payment of approximately $2 billion to cover its share of capital expenditures incurred from the effective date to closing.
James Wyper, Senior Managing Director and Head of US Private Equity at Stonepeak, said, "The Project represents a compelling opportunity to invest in a newbuild LNG export facility nearing FID approval with an attractive risk-return profile and best-in-class partners in both Bechtel and Woodside to<a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44659501/stonepeak-to-acquire-interest-in-woodsides-louisiana-lng" rel="noreferrer noopener"> construct and operate the asset."</a>
Price Action: WDS shares are down 0.82% at $11.54 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42743811/chart-industries-secures-11-million-lng-deal-with-bechtel-and-woodside-energy" target="_blank" rel="noreferrer noopener">Chart Industries Lands LNG Deal: Powering Woodside Energy's Louisiana Expansion</a></li>
</ul>
Image via Shutterstock

Equities

Large Cap

Asset Sales

Woodside Energy Sells 40% Stake In Louisiana LNG Project For $5.7 Billion

President Trump Says U.S. Will Impose Additional 50% Tariffs On China Effective April 9th If China Does Not Withdraw 34% Increase; All Talks With China Concerning Requested Meetings With U.S. Will Be Terminated

Note: CNBC Misquotes Old Interview Of Hassett On Fox, Which Was Then Posted By Reuters And Then Circulated On Social Media; White House Says Hassett Headline Is 'Fake News'

Barclays analyst Andrew Lazar maintains Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) with a Overweight and raises the price target from $27 to $29.

Barclays Maintains Overweight on Conagra Brands, Raises Price Target to $29

Health Care

Press Releases

Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Receptor Agonists

PMGC Holdings Highlights Strong Capital Position: No Debt, Fully Funded, and Warrants Priced Above Market

PMGC Holdings Inc. Expands Investment & M&A Efforts, Actively Seeking Acquisitions and Investments Through Strategic Sponsorship of TCA Venture Group

PMGC Holdings Inc. Announces Reverse Stock Split to Maintain Nasdaq Listing Compliance

Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1

PMGC Holdings Announces Share Repurchases from Existing Shareholders

PMGC Holdings Inc. Announces $1.48 Million Registered Direct Offering Priced At-The Market Under Nasdaq Rules

Univest Securities, LLC Announces Closing of $1.48 Million Registered Direct Offering for its Client PMGC Holdings Inc. (NASDAQ: ELAB)

NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market

PMGC Holdings Inc. Announces Filing of Annual Report on Form 10-K

ELAB

AXIL Brands

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

PMGC Holdings

Flora Growth

Mannatech

Natural Alternatives International, Inc. - Common Stock

Natural Alternatives Intl

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Entertainment

Safety Shot

Shineco

Synergy CHC

United-Guardian

Upexi

Eon Labs

Screenshot 2024-05-25 at 12.27.19 AM

Biotech

Interview

Ozempic And Wegovy Can Lead To Major Muscle Loss – This Company May Have A Solution

Screenshot 2024-05-16 at 5.52.00 PM

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Comments

PMGC Holdings

Notizie

Ultime notizie per PMGC Holdings (NASDAQ:ELAB) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO